ArticleBioengineering & translational medicine2026
Engineering human peritoneum in vitro: A novel microfluidic platform for modeling peritoneal physiology and pathophysiology.
Article in Bioengineering & translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The peritoneum, the body's largest serous membrane, plays critical roles in abdominal homeostasis and immune defense. When disrupted by surgery or disease, it can lead to devastating complications including peritoneal adhesions-affecting up to 93% of surgical patients-peritonitis, and metastatic spread. Current research models fail to capture the complexity of human peritoneal biology, relying on inadequate animal models or oversimplified 2D cultures. Here, we introduce a PDMS-free microfluidic platform that recreates the structural and functional architecture of human peritoneum. Our system combines immortalized mesothelial cells (MeT5A) with patient-derived peritoneal fibroblasts in a physiologically relevant 3D environment, enabling real-time analysis of peritoneal function and dysfunction. Through systematic evaluation of stromal matrices, we identified fibrin gel as optimal for supporting healthy mesothelial monolayer formation while maintaining excellent cell viability over 14 days. Importantly, we demonstrate the platform's translational potential by successfully modeling peritoneal adhesion formation. This innovative tool may improve the understanding of peritoneal biology, accelerating drug discovery and developing personalized treatment strategies for peritoneal diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.